Medicare Hospice CTI Admission Note Requirements for Hypertensive Heart Disease
For Medicare hospice admission with hypertensive heart disease, the CTI (Continuity of Care) note must document terminal prognosis indicators including NYHA Class IV symptoms, ejection fraction ≤20%, refractory symptoms despite optimal medical therapy, recurrent hospitalizations, and specific clinical markers that establish a 6-month or less life expectancy.
Essential Documentation Elements
Patient Demographics and Identification
Document complete patient identifiers including name, date of birth, medical record number, and Social Security number for Medicare billing purposes 1.
Hypertensive Heart Disease Diagnosis Documentation
Blood Pressure History:
- Document hypertension diagnosis with specific criteria: history of BP >140/90 mmHg on at least 2 occasions, or BP >130/80 mmHg for patients with diabetes or chronic kidney disease 1
- Year of onset (first diagnosis) 1
- Treatment history including medications, diet, and exercise interventions 1
Cardiac Structural Changes:
- Left ventricular ejection fraction (EF) - quantitative value preferred, with modality specified (echocardiography, MRI, radionuclide ventriculography, or contrast ventriculography) 2
- Left ventricular hypertrophy presence and severity 2
- Chamber dilation status 2
- Valvular dysfunction (stenosis or regurgitation) if present 1
Terminal Prognosis Indicators (Critical for Medicare Eligibility)
Functional Status:
- NYHA Class IV symptoms: marked limitation with symptoms at rest 3, 4
- Inability to perform activities of daily living 4
- Recent decline in functional capacity 4
Clinical Markers of Advanced Disease:
- Ejection fraction ≤20% (or ≤25% with additional high-risk features) 5
- Recurrent hospitalizations for heart failure (document frequency and dates) 5
- Refractory symptoms despite optimal medical therapy 3
- Persistent dyspnea at rest 3
- Persistent edema despite diuretic therapy 6
- Systolic blood pressure ≤90 mmHg 5
Laboratory Values:
- Serum sodium ≤130 mEq/L 5
- Blood urea nitrogen ≥45 mg/dL 5
- Elevated cardiac biomarkers if available 2
- Renal function (serum creatinine, eGFR) 4
Comprehensive Medical History
Cardiovascular Risk Factors and Comorbidities:
- Diabetes mellitus (type, year of onset, treatment method: none, diet, oral agents [specify: metformin, sulfonylureas, TZDs], insulin, or combination) 1
- Dyslipidemia (total cholesterol, LDL, HDL values; lipid-lowering therapy) 1
- Prior myocardial infarction (dates, ECG findings, biomarker elevations) 7
- Coronary artery disease (prior CABG, PCI, angiographic findings) 7
- Atrial fibrillation or other arrhythmias 7
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²) 8
- Stroke or TIA history (dates, severity, residual deficits) 7
Other Relevant History:
- Alcohol consumption/dependency (quantify: none, ≤1 drink/week, 2-7 drinks/week, ≥8 drinks/week; document dependency treatment) 1
- Tobacco use history 9
- Thyroid disorder 1
- Obesity (BMI) 9
Current Symptoms and Physical Examination
Symptom Documentation:
- Dyspnea severity and frequency 6
- Chest pain characteristics 6
- Orthopnea and paroxysmal nocturnal dyspnea 4
- Fatigue and exercise intolerance 4
Physical Findings:
- Current blood pressure (both arms if first visit) 10
- Orthostatic blood pressure changes 4
- Weight and BMI 4
- Volume status assessment (jugular venous distension, rales, peripheral edema location and severity) 4, 6
Current Medication Regimen
Document all cardiac medications with specific details:
- ACE inhibitors/ARBs (drug name, dose, frequency) 10
- Beta-blockers (drug name, dose, frequency) 10
- Diuretics (type: thiazide, loop, or potassium-sparing; dose, frequency) 10
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) 8, 11
- Calcium channel blockers 10
- Digoxin 4
- Vasodilators (hydralazine/nitrates) 4
- Medication intolerances or contraindications (critical but often missing) 6
Device History
- Pacemaker presence and type 6
- Implantable cardioverter-defibrillator (ICD) - document deactivation discussion per hospice philosophy 3
- Cardiac resynchronization therapy (CRT) device 4
Hospitalizations and Healthcare Utilization
- Recent hospitalizations (dates, reasons, length of stay) 5
- Emergency department visits 5
- Intensive care unit admissions 3
Goals of Care and Advance Directives
- Patient/family understanding of terminal prognosis 3
- Do-not-resuscitate (DNR) status 3
- Healthcare proxy or power of attorney designation 3
- ICD deactivation decision (if applicable) 3
- Specific interventions patient wishes to forego (e.g., hospitalization, IV diuretics) 3
Critical Documentation Gaps to Avoid
Common pitfalls identified in hospice admissions 6:
- Missing left ventricular ejection fraction data (provided only 50% of the time)
- Incomplete medication intolerance history (rarely documented)
- Absent blood pressure readings at admission
- Missing comorbidity documentation
- Inadequate device information
Clinical Context
The research evidence reveals that hospice discharge for heart failure patients has increased to 4.9% of Medicare discharges, with significant hospital variation 5. However, almost 25% of patients discharged to hospice die within 3 days, suggesting many referrals occur very late in the disease course 5. This underscores the importance of thorough documentation to justify the terminal prognosis while also recognizing that approximately 15% of hospice-admitted heart failure patients survive 6 months or longer 5.
The CTI note must establish that the patient meets Medicare's 6-month prognosis requirement through objective clinical data, not subjective impressions alone. The combination of severely reduced ejection fraction, refractory symptoms despite maximal therapy, recurrent hospitalizations, and specific laboratory abnormalities provides the strongest documentation for terminal status 5.